We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Neutrophil-Lymphocyte Ratio Proves Possible Biomarker for ED

By LabMedica International staff writers
Posted on 30 May 2019
Erectile dysfunction is described as the impotency to obtain or sustain an erection sufficiently in order to enable convincing sexual intercourse. More...
Erectile dysfunction (ED) is estimated to affect about 75% of men over the age of 75 and 20% of men over the age of 20.

The association among many diseases, inflammatory markers and also their roles in the disease etiopathogenesis are important. The literature reveals that emerge and severity of ED are related with markers and mediators of inflammation and endothelial dysfunction.

Urologists at the Ordu University (Ordu, Turkey) and their colleagues evaluated 90 patients with erectile dysfunction (ED) and 94 healthy subjects from their internal medicine and urology clinics. As diagnosis criteria, they used the first five questions of International Index for Erectile Function. The duration of erectile dysfunction was asked and recorded. Height, weight and waist circumference of patients were measured.

The team performed total blood count, sedimentation, C-reactive protein, blood urea nitrogen (BUN), creatine, cholesterol, Low-density lipoprotein cholesterol (LDL-C) and High-density lipoprotein cholesterol (HDL-C) measurements of the patients were recorded. The neutrophil-lymphocyte ratio (NLR) was computed as the total neutrophil count separated by the total lymphocyte count.

The investigators found that there were statistically significant differences in terms of NLR between the control 1.038 (range: 0.507-1.92) and ED 2.38 (1.67.0-3.00) groups. According to the multivariate logistic regression analysis, duration of ED (Cut off: 7.5 month) predicted ED with 78.8% sensitivity and 63.1% specificity (AUC: < 0.001). Moreover, NLR (Cut off: 1.574) predicted ED with 81.8% sensitivity and 67.0% specificity (AUC: < 0.001) according to the multivariate logistic regression analysis.

The authors concluded that that the neutrophil-lymphocyte ratio was higher in patient group than the control group, and that the neutrophil-lymphocyte ratio (NLR) predicted ED and it might be helpful in diagnosing erectile dysfunction. The study was published on May 5, 2019, in the Urology Journal.

Related Links:
Ordu University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.